Summary

Start-ups in Silicon Valley are advancing germline editing with genetic modification of embryos – a technology that could prevent serious hereditary diseases but also leads to "designer babies." Following the ethical scandal involving Chinese researcher He Jinkui, who created the first genetically modified twins in 2018, companies like Manhattan Genomics are pushing into a regulatory vacuum. Scientists warn: Germline editing is technologically still too unsafe and raises fundamental questions about society.

People

Topics

  • CRISPR gene scissors and gene editing
  • Germline vs. somatic editing
  • Bioethics and designer babies
  • Regulation and Silicon Valley start-ups

Clarus Lead

The CRISPR gene scissors enable precise DNA modifications – yet while somatic therapies treat individual people, germline editing would affect millions of future generations. Start-ups like Manhattan Genomics promise to eradicate hereditary diseases, but experts criticize: The technology is still too dangerous, off-target effects are unavoidable. Following He Jinkui's failed experiment with genetically modified twins (2018), new actors are emerging in the regulatory vacuum – with investors from cryptocurrency exchanges and AI companies who adopt "move fast and break things" as their motto.

Detailed Summary

Technology and Clinical Application

CRISPR-Cas works like a precise scissors: The Cas protein cuts DNA at exact locations and allows defective genes to be removed or corrected. Since 2023, there have been first clinical successes – for example, therapy for sickle cell anemia, which only affects individual patients (somatic editing). A toddler was successfully healed in 2025 with customized gene editing. The crucial difference: In somatic editing, only body cells are modified and the change is not inherited. In germline editing, the modification occurs in the embryo – all cells of the future human carry the mutation, including egg cells or sperm cells that are passed on to future generations.

The He Jinkui Scandal and Its Aftermath

In 2018, Chinese researcher He Jinkui created the world's first genetically modified babies – twins and a third child, manipulated for HIV resistance. The approach was ethically catastrophic: He exposed healthy children to enormous risks (the method was still unsafe), insufficiently informed parents, and caused off-target effects (unintended DNA cuts). He Jinkui spent three years in Chinese prison. His manuscripts were never published, but some researchers saw them. In April 2025, He Jinkui married Cathy Tai, the founder of Manhattan Genomics – and announced a new company called KC Medicine to edit embryos. The two now claim to work independently, but observers suspect collaboration.

Start-ups Push into the Vacuum

Besides Manhattan Genomics, there are at least two other start-ups: Preventive (founder Lukas Herrington, funded by Coinbase CEO Brian Armstrong and Sam Altman's husband) and Putstrap Bio (Chase Denneke; minimal public information). Putstrap Bio explicitly advertises optimizations – not just disease prevention. In Silicon Valley, a pro-natalist movement shapes the scene: investors see declining birth rates as an existential threat and want "better" babies. The business model is tempting: parents can already choose embryos based on genetic traits today (hair color, eye color, intelligence potential, cancer risk) – without editing, just through selection. The next step: genetic enhancement itself.

Scientific Risks and Ethical Boundaries

Germline editing harbors unresolved problems. Off-target effects are documented – the CRISPR scissors sometimes cut at wrong locations. If a gene affected protects against cancer, cancer risk increases significantly. Intelligence and body height are polygenic (many genes involved) – a single modification achieves little. Hair color and eye color are monogenic (one gene) – editing would be simpler there, but scientifically controversial. Jacob Corn (ETH Zurich) compares somatic editing to paracetamol: It heals my headache. Germline editing would be "magic paracetamol" – it would also heal all my descendants. That is the potential – and the danger.

Key Statements

  • CRISPR is clinically established for somatic therapies (sickle cell anemia, individual children), but germline editing remains banned in most countries (EU, USA, China) – too dangerous.

  • Off-target effects are unavoidable: Unintended DNA cuts can trigger cancer or cause other damage that propagates across generations.

  • Silicon Valley start-ups circumvent regulation: With investors from cryptocurrency exchanges and AI firms, they operate in a vacuum and could relocate to countries with laxer laws (Honduras) or benefit from Trump deregulation.

  • Designer baby scenarios are closer than expected: Today, parents can already select embryos; editing could succeed commercially within 3 years – or fail.

  • Societal boundary-setting is necessary: Is disease prevention ethically justifiable? When does it become "optimization"? These questions require transparent, open debates.

Critical Questions

  1. Evidence quality (a): He Jinkui's manuscripts were never peer-reviewed and published; can start-ups substantiate their safety promises with studies on mice, primates, or embryos before treating humans?

  2. Off-target verification (a): How reliably can current methods guarantee that CRISPR cuts only at the targeted gene and not at hundreds of other locations?

  3. Conflicts of interest (b): To what extent do investors from cryptocurrency exchanges (Armstrong/Coinbase) and AI firms (Altman/OpenAI) influence the pace and ethical standards of Preventive and Manhattan Genomics?

  4. Regulatory gaps (b): Which countries could start-ups relocate to if the USA loosens regulations under Trump – and who monitors these experiments then?

  5. Intelligence causality (c): How many genes actually influence intelligence, and can a single CRISPR edit have a measurable effect, or are these scientifically dubious promises?

  6. Generational consequences (d): If off-target effects only become visible in the third generation (e.g., increased cancer risk), who bears responsibility – the start-up, the parents, or the state?

  7. Transparency vs. competition (d): How can we ensure that start-up research into germline editing remains open and verifiable when trade secrets and profit pressure argue against it?

  8. Societal consensus (d): Who should decide whether germline editing is permitted – scientists, investors, ethicists, or society via referendum?

Source List

Primary Source: Quantensprung – CRISPR gene scissors: Designer babies within reach? NCZ, 23.02.2026 https://audio.podigee-cdn.net/2365237-m-e2660336f9c64466521eb47fc5d02eaf.mp3?source=feed

Supplementary Sources:

  1. Jacob Corn, ETH Zurich – Genomics and somatic editing
  2. Jennifer Doudna, UC Berkeley – CRISPR development (2012)
  3. Ormond, ETH Zurich – Bioethics and germline editing

Verification Status: ✓ 2026-02-23

This text was created with the support of an AI model. Editorial responsibility: clarus.news | Fact-check: 2026-02-23